Business Wire (Thu, 4:00PM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
789 people get ALKS articles and Market Currents by email alert.
Get email alerts on ALKS »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
Business Wire (Thu, 7:00AM)
-
-
Business Wire (May 1, 2013)
-
-
-
-
Business Wire (Apr 17, 2013)
-
-
-
-
-
-
Business Wire (Feb 19, 2013)
-
Lundbeck Could Cheer Up Patient InvestorsStephen Simpson • Wed, Feb 13
-
Business Wire (Feb 5, 2013)
-
Business Wire (Jan 31, 2013)
-
-
-
-
-
Alkermes Narrows Loss on Higher RevenueZacks Investment Research • Thu, Aug 4, 2011 -
Alkermes Earnings PreviewZacks Investment Research • Mon, Jan 31, 2011
-
-
Alkermes Outlook Remains BleakZacks Investment Research • Tue, May 26, 2009
-
Is A New Blockbuster Drug In The Works For Alkermes?Steven T. Gold • Mon, Jun 4, 2007
-
-
-
-
-
-
-
-
Lundbeck Could Cheer Up Patient InvestorsStephen Simpson • Wed, Feb 13
-
-
-
-
3 Highly Liquid Mid Caps With Strong Growth ProjectionsZetaKap • Thu, Sep 6, 2012 -
8 Highly Liquid Healthcare Stocks Undervalued By EPS TrendsKapitall • Thu, Aug 23, 2012 -
-
-
-
-
-
-
-
Alkermes' CEO Discusses F2Q13 Results - Earnings Call TranscriptThu, Nov 1, 2012
-
Alkermes' CEO Discusses F1Q13 Results - Earnings Call TranscriptThu, Jul 26, 2012
-
Alkermes CEO Discusses F2Q2011 Results - Earnings Call TranscriptSun, Nov 7, 2010
-
Alkermes Q1 2011 Earnings Conference Call TranscriptFri, Aug 6, 2010
-
Alkermes Inc. F4Q10 (Qtr End 03/31/10) Earnings Call TranscriptThu, May 13, 2010
-
Alkermes, Inc. F3Q10 (Qtr End 12/31/09) Earnings Call TranscriptThu, Feb 4, 2010
-
Alkermes, Inc. Q3 2009 Earnings Call TranscriptTue, Feb 17, 2009
-
Alkermes, Inc. F2Q09 (Qtr End 09/30/08) Earnings Call TranscriptTue, Nov 18, 2008
-
Alkermes, Inc F1Q09 (Qtr End 06/30/08) Earnings Call TranscriptThu, Aug 7, 2008
-
Alkermes Inc. F408 (Qtr End 03/31/2008) Earnings Call TranscriptThu, May 22, 2008
-
Alkermes Inc., F3Q08 (Qtr End 12/31/07) Earnings Call TranscriptSun, Feb 10, 2008
-
Business Wire (Thu, 4:00PM)
-
Business Wire (Thu, 7:00AM)
-
Business Wire (May 1, 2013)
-
Business Wire (Apr 17, 2013)
-
at CNBC.com (Feb 27, 2013)
-
Business Wire (Feb 19, 2013)
-
Business Wire (Feb 5, 2013)
-
Business Wire (Jan 31, 2013)
-
Business Wire (Jan 24, 2013)
-
Business Wire (Jan 2, 2013)
-
Business Wire (Nov 7, 2012)
-
Business Wire (Nov 1, 2012)
-
Business Wire (Oct 25, 2012)
-
Business Wire (Sep 25, 2012)
-
Business Wire (Sep 19, 2012)
-
Business Wire (Aug 30, 2012)
-
at Fox Business (Aug 20, 2012)
ALKS vs. ETF Alternatives
Company Description
Alkermes, Inc. is a fully integrated biotechnology company committed to developing innovative medicines to improve patients’ lives. We developed, manufacture and commercialize VIVITROL® for alcohol dependence and manufacture RISPERDAL® CONSTA® for schizophrenia and bipolar disorder. Our... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, May 16, 12:05 AM Notable earnings before Thursday’s open: ALKS, DANG, FLO, KSS, SOL, WMT Comment! [Earnings]
- Wednesday, May 15, 5:30 PM Notable earnings before Thursday’s open: ALKS, DANG, FLO, KSS, SOL, WMT Comment! [Earnings]
- Friday, April 26, 10:47 AM Analysts continue to sound a cautious tone regarding Alkermes' (ALKS -2.1%) MDD drug candidate ALKS5461 after positive Phase II trial data generated quite a buzz last week. "We appreciate the significant market opportunity for this drug [but] challenges could lie ahead for this product," notes BofA analyst Steve Byrne who downgrades the stock to Underperform (price target raised to $29). "We value 5461 at $2.50 per share," he adds. Both Lazard and Mizuho also seem tentative on the stock (I, II). Comment! [Healthcare, On the Move]
- Monday, April 22, 10:01 AM Lazard Capital makes a valuation call on Alkermes (ALKS -1.3%), downgrading the stock to Neutral from Buy after last week's run-up. Mizuho had a similar call on Thursday as sentiment seems to be that Phase III trial data is too far out to justify the enthusiasm surrounding top line results from Phase II clinicals. Comment! [Healthcare]
- Thursday, April 18, 11:10 AM "Under promise, over deliver," says Cramer of Alkermes (ALKS -0.5%) after the company says its major depressive drug ALKS5461 shows promise in Phase II clinicals. "This drug may work for people who can't take Prozac," Cramer adds. Mizuho however, says the shares may be ahead of themselves and downgrades the stock to Neutral from Buy while shaving its price target to $26. Comment! [Healthcare]
-
Wednesday, April 17, 12:59 PM
Midday top 10 gainers: ACUR +53%. ECTY +16%. PCYG +16%. ALKS +15%. OCZ +15%. OGEN +14%. RECV +12%. CASM +11%. ATLS +11%. CHLN +11%.
Midday top 10 losers: EOPN -26%. CNIT -26%. INWK -25%. MHR -21%. CXW -18%. CRMB -16%. CRUS -16%. EPAX -14%. BMI -14%. EMXX -14%. Comment! [On the Move] -
Wednesday, April 17, 9:12 AM
Premarket gainers: VRML +29%. ACUR +26%. OCZ +18%. CUR +9%. ALKS +9%. ABMD +9%. ASML +6%.
Losers: EOPN -29%. INWK -25%. CXW -15%. MHR -12%. ZGNX -11%. TXT -9%. CRUS -7%. VRNG -6%. 1 Comment [On the Move] - Wednesday, April 17, 7:51 AM Alkermes (ALKS) says preliminary top line results from a Phase II clinical study of the major depressive disorder drug ALKS5461 are positive as depressive symptoms were significantly reduced and the treatment is well tolerated. The company will now move to meet with the FDA to move the drug into a pivotal development program. Comment! [Healthcare]
-
Friday, February 1, 9:10 AM
Premarket gainers: ADNC +30%. TSYS +15%. RAD +9%. CTRP +8%. EDAP +7%. ALU +6%. DELL +6%. VVUS +5%. PRGO +5%.
Losers: ECTE -35%. OTT -23%. LTM -16%. SDR -11%. OCZ -8%. CLSN -7%. ALKS -7%. NMM -6%. TLAB -5%. Comment! [On the Move] - Thursday, January 31, 5:43 PM Elan (ELN) says it's unloading its remaining 7.75M share stake in Alkermes (ALKS). The sale will be made through Jefferies, and is expected to close on February 6. ELN received 31.9M shares in September, 2011, after merging its drug technology business with ALKS. It sold the first tranche of 24.15M shares back in March, 2012. Comment! [Healthcare]
- Thursday, January 31, 12:12 PM Shares of Alkermes (ALKS +2.3%) move up today after its FQ3 easily beats bottom line estimates. Revenue grew by 8.2% Y/Y, driven by a 33% jump in sales of its five key commercial lines. For FY13, the company raises guidance above Street estimates, now expecting to earn between $0.99 - $1.13 per share. Analysts were expecting an EPS of $0.95. Comment! [On the Move, Earnings, Healthcare]
- Thursday, January 31, 7:10 AM Alkermes (ALKS): Q4 EPS of $0.34 beats by $0.11. Revenue of $135.9M (+8.2% Y/Y) beats by $5.09M. (PR) 1 Comment [Earnings, Breaking News, Healthcare]
- Thursday, January 31, 12:05 AM Notable earnings before Thursday’s open: AET, ALKS, AN, APU, AZN, BEAV, BLL, BMS, BX, CAM, CL, CNH, CNX, COCO, CRR, D, DB, DNKN, DOW, EPD, ERIC, EXXI, HAR, HGG, HP, HSH, HSY, IVZ, LQDT, MA, MJN, MO, MTG, MWW, NDAQ, NVO, OXY, PBI, PCAR, PENN, PHM, POT, R, RCL, RGLD, SHW, TE, TEN, TMO, TWC, UA, UGI, UPS, VIAB, WHR, XEL, ZMH Comment! [Earnings]
- Wednesday, January 30, 5:30 PM Notable earnings before Thursday’s open: AET, ALKS, AN, APU, AZN, BEAV, BLL, BMS, BX, CAM, CL, CNH, CNX, COCO, CRR, D, DB, DNKN, DOW, EPD, ERIC, EXXI, HAR, HGG, HP, HSH, HSY, IVZ, LQDT, MA, MJN, MO, MTG, MWW, NDAQ, NVO, OXY, PBI, PCAR, PENN, PHM, POT, R, RCL, RGLD, SHW, TE, TEN, TMO, TWC, UA, UGI, UPS, VIAB, WHR, XEL, ZMH Comment! [Earnings]
- Thursday, January 17, 1:31 PM Shares of Alkermes (ALKS -0.4%) fail to get a spark from todays buying, largely due to Credit Suisse initiating the stock with a tepid Neutral rating and lackluster $24 price target. The firm says ALKS has an enticing long-term story, but its recent run (the stock is already +21% YTD versus +7% for its peers) leaves the broker looking for a better entry point. Additionally, a potentially negative readout for its depression drug candidate ALKS 5461 poses near-term risks. 1 Comment [Healthcare, On the Move]
- Thursday, November 1, 2012, 8:27 AM Alkermes (ALKS): FQ2 EPS of $0.17 beats by $0.06. Revenue of $124M (+72% Y/Y) beats by $3M. (PR) Comment! [Earnings, Healthcare]
-
- View all 1 replies
-
Michael Bryant: $ALKS & $SHW have each rose 3 times out of the past 6 business days on unusual volume.
-
Michael Bryant
Alkermes plc ($ALKS), Qihoo 360 Technology ($QIHU), & P.T. Telekomunikasi Indonesia ($TLK) rose Wednesday on unusual volume. - View all 1 replies
-
Michael Bryant: $TLK is doing well, but I am wondering how high it can go. $TLK seems to me the $T of Indonesia.
-
- View all 0 replies
-
- View all 1 replies
-
-
- View all 0 replies
-
Capitalist Bull
Stock Market - Further downside remains. Cash or Trade Only. http://stks.co/jCSR AAPLGOOD RAX ALKS DDD LNKD YNDX QIHU SPY QQQ - View all 0 replies
-
- View all 0 replies
-
Capitalist Bull
#LeadingStocks Up on #Volume: $GOOG $DHI $SSYS $HOS $AGU $CLMT $ALKS $PCLN http://bit.ly/MwUXlb - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES
-
- View all 1 replies
-
Michael Bryant: $ALKS & $SHW have each rose 3 times out of the past 6 business days on unusual volume.
-
Michael Bryant
Alkermes plc ($ALKS), Qihoo 360 Technology ($QIHU), & P.T. Telekomunikasi Indonesia ($TLK) rose Wednesday on unusual volume. - View all 1 replies
-
Michael Bryant: $TLK is doing well, but I am wondering how high it can go. $TLK seems to me the $T of Indonesia.
-
- View all 1 replies
-